Jasper Therapeutics Inc (JSPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.71+3.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · JSPR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Cost of Revenues | 23.3 | 41.6 | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||
| R&D Expenses | 36.7 | 63.1 | 55.8 | 51.8 | 34.6 | 25.4 | 15.9 | — |
| Operating Income | (55.2) | (83.9) | (76.2) | (68.9) | (51.2) | (36.8) | (20.7) | — |
| Earnings from Continuing Operations | ||||||||
| Interest & Investment Income | 0.9 | 1.7 | 5.1 | 5.2 | 0.7 | — | — | — |
| Other Non-Operating Income / Expenses | 23.4 | 8.1 | 5.0 | 4.4 | — | — | — | — |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | (6.4) | — |
| Income Tax Expense | — | — | 0.0 | 0.0 | — | — | 0.0 | — |
| Net Income | ||||||||
| Net Income | 44.0 | (75.8) | (71.3) | (64.5) | (37.7) | (30.6) | (31.7) | — |
| Per Share | ||||||||
| Basic EPS | 1.53 | (3.95) | (4.89) | (6.18) | (10.33) | (2.69) | — | — |
| Diluted EPS | 1.53 | (3.95) | (4.89) | (6.18) | (10.33) | (2.69) | — | — |
| Basic Weighted Avg Shares | 28.7 | 19.2 | 14.6 | 10.4 | 3.6 | 11.4 | — | — |
| Diluted Weighted Avg Shares | 28.7 | 19.2 | 14.6 | 10.4 | 3.6 | 11.4 | — | — |
| Supplemental | ||||||||
| EBITDA | — | (82.8) | (74.9) | (67.8) | (50.2) | (36.5) | — | — |
| EBIT | (55.2) | (83.9) | (76.2) | (68.9) | (51.2) | (36.8) | (20.7) | — |
| Effective Tax Rate | — | — | — | — | — | — | -0.6% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.